Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jan 16 · below the Ichimoku cloud · RSI 49 · MACD above its signal
| 3.20 | 52-week high | +126.15% |
| 1.66 | Previous month high | +17.31% |
| 1.53 | Previous week high | +8.13% |
| 1.52 | R3 (classic) | +7.42% |
| 1.49 | R2 (classic) | +4.95% |
| 1.45 | Previous day high | +2.47% |
| 1.45 | R1 (classic) | +2.47% |
| 1.42 | Pivot | +0.00% |
| 1.42 | Price now | |
| 1.38 | Previous day low | −2.47% |
| 1.38 | S1 (classic) | −2.47% |
| 1.35 | Previous week low | −4.59% |
| 1.34 | S2 (classic) | −4.95% |
| 1.31 | S3 (classic) | −7.42% |
| 1.28 | Previous month low | −9.54% |
| 1.26 | 52-week low | −10.60% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $16.8K | 0.00% | 11.20K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a OKYO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for OKYO.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.0 | -16.6 | -5.8 | -3.1 | 9.9 | -12.5 | 12.0 | -9.5 | -15.1 | 9.7 | −31.6% | ||
| 2025 | -7.8 | 18.9 | 0.8 | 24.8 | 16.7 | 38.9 | 5.1 | -13.0 | -14.9 | 37.0 | -28.5 | 5.6 | +80.0% |
| 2024 | -16.4 | -10.1 | 12.0 | 0.7 | -0.7 | -20.1 | 3.4 | -2.4 | -15.0 | 15.7 | -13.5 | 12.6 | −35.0% |
| 2023 | 31.9 | -11.5 | -24.7 | -25.0 | 23.8 | -26.5 | 63.2 | 7.5 | -8.0 | -10.3 | -1.8 | 8.6 | −7.3% |
| 2022 | 2.4 | 11.9 | 11.5 | 0.4 | -13.7 | -13.2 | -3.0 | −6.8% |
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Buy / hold / sell counts